Korean J Gastroenterol.  2018 May;71(5):253-259. 10.4166/kjg.2018.71.5.253.

Management of Gallstone

• Yoo KS

• KMID: 2415482
• DOI: http://doi.org/10.4166/kjg.2018.71.5.253

Abstract

Gallstones are one of the most common diseases worldwide. Recently, the incidence of gallstones has increased and the pattern of gallstones has changed in Korea. Laparoscopic cholecystectomy is the standard treatment for symptomatic gallstones. Expectant management is considered the most appropriate choice in patients with asymptomatic gallstones. The dissolution of cholesterol gallstones by oral bile acid, such as ursodeoxycholic acid, can be considered in selected patients with gallstones. Although the advent of laparoscopic cholecystectomy has moved interest away from the pharmacologic treatment of gallstones, several promising agents related to various mechanisms are under investigation.

Keyword

Gallstones; Therapeutics

MeSH Terms

Bile
Cholecystectomy, Laparoscopic
Cholesterol
Gallstones*
Humans
Incidence
Korea
Ursodeoxycholic Acid
Cholesterol
Ursodeoxycholic Acid

Reference

References

1. Lammert F, Gurusamy K, Ko CW, et al. Gallstones. Nat Rev Dis Primers. 2016; 2:16024.

2. Everhart JE, Ruhl CE. Burden of digestive diseases in the United States part III: liver, biliary tract, and pancreas. Gastroenterology. 2009; 136:1134–1144.

3. Aerts R, Penninckx F. The burden of gallstone disease in Europe. Aliment Pharmacol Ther. 2003; 18(Suppl 3):49–53.

4. Diehl AK, Sugarek NJ, Todd KH. Clinical evaluation for gallstone disease: usefulness of symptoms and signs in diagnosis. Am J Med. 1990; 89:29–33.

5. Lee J. Clinical manifestation and diagnosis of the gallstones. Chung JB, editor. Diseases of the gallbladder and bile ducts. 1st ed.Seoul: Koonja Publishing;2008. p. 189–210.

6. Gibney EJ. Asymptomatic gallstones. Br J Surg. 1990; 77:368–372.

7. Rigas B, Torosis J, McDougall CJ, Vener KJ, Spiro HM. The circadian rhythm of biliary colic. J Clin Gastroenterol. 1990; 12:409–414.

8. Traverso LW. Clinical manifestations and impact of gallstone disease. Am J Surg. 1993; 165:405–409.

9. Yoo KS. Diagnosis of gallstone. Korean J Med. 2008; 75:616–623.

10. Thistle JL, Cleary PA, Lachin JM, Tyor MP, Hersh T. The natural history of cholelithiasis: the national cooperative gallstone study. Ann Intern Med. 1984; 101:171–175.

11. Friedman GD, Raviola CA, Fireman B. Prognosis of gallstones with mild or no symptoms:25 years of follow-up in a health maintenance organization. J Clin Epidemiol. 1989; 42:127–136.

12. Portincasa P, Moschetta A, Palasciano G. Cholesterol gallstone disease. Lancet. 2006; 368:230–239.

13. Tazuma S, Unno M, Igarashi Y, et al. Evidencebased clinical practice guidelines for cholelithiasis 2016. J Gastroenterol. 2017; 52:276–300.

14. Mayo WJ. Innocent gallstones a myth. JAMA. 1911; LVI:1021–1024.

15. Gracie WA, Ransohoff DF. The natural history of silent gallstones: the innocent gallstone is not a myth. N Engl J Med. 1982; 307:798–800.

16. Attili AF, De Santis A, Capri R, Repice AM, Maselli S. The natural history of gallstones: the GREPCO experience. The GREPCO group. Hepatology. 1995; 21:655–660.

17. McSherry CK, Ferstenberg H, Calhoun WF, Lahman E, Virshup M. The natural history of diagnosed gallstone disease in symptomatic and asymptomatic patients. Ann Surg. 1985; 202:59–63.

18. Cucchiaro G, Rossitch JC, Bowie J, et al. Clinical significance of ultrasonographically detected coincidental gallstones. Dig Dis Sci. 1990; 35:417–421.

19. Zubler J, Markowski G, Yale S, Graham R, Rosenthal TC. Natural history of asymptomatic gallstones in family practice office practices. Arch Fam Med. 1998; 7:230–233.

20. Sakorafas GH, Milingos D, Peros G. Asymptomatic cholelithiasis: is cholecystectomy really needed? A critical reappraisal 15 years after the introduction of laparoscopic cholecystectomy. Dig Dis Sci. 2007; 52:1313–1325.

21. Guarino MP, Cocca S, Altomare A, Emerenziani S, Cicala M. Ursodeoxycholic acid therapy in gallbladder disease, a story not yet completed. World J Gastroenterol. 2013; 19:5029–5034.

22. Festi D, Reggiani ML, Attili AF, et al. Natural history of gallstone disease: expectant management or active treatment? Results from a population-based cohort study. J Gastroenterol Hepatol. 2010; 25:719–724.

23. Shabanzadeh DM, Sørensen LT, Jørgensen T. A prediction rule for risk stratification of incidentally discovered gallstones: results from a large cohort study. Gastroenterology. 2016; 150:156–167.e1.

24. Friedman GD. Natural history of asymptomatic and symptomatic gallstones. Am J Surg. 1993; 165:399–404.

25. Portincasa P, Ciaula AD, Bonfrate L, Wang DQ. Therapy of gallstone disease: what it was, what it is, what it will be. World J Gastrointest Pharmacol Ther. 2012; 3:7–20.

26. Deziel DJ, Millikan KW, Economou SG, Doolas A, Ko ST, Airan MC. Complications of laparoscopic cholecystectomy: a national survey of 4,292 hospitals and an analysis of 77,604 cases. Am J Surg. 1993; 165:9–14.

27. Lowenfels AB, Lindström CG, Conway MJ, Hastings PR. Gallstones and risk of gallbladder cancer. J Natl Cancer Inst. 1985; 75:77–80.

28. Randi G, Franceschi S, La Vecchia C. Gallbladder cancer worldwide: geographical distribution and risk factors. Int J Cancer. 2006; 118:1591–1602.

29. Ashur H, Siegal B, Oland Y, Adam YG. Calcified ballbladder (porcelain gallbladder). Arch Surg. 1978; 113:594–596.

30. Bonatsos G, Birbas K, Toutouzas K, Durakis N. Laparoscopic cholecystectomy in adults with sickle cell disease. Surg Endosc. 2001; 15:816–819.

31. Plecka Östlund M, Wenger U, Mattsson F, Ebrahim F, Botha A, Lagergren J. Population-based study of the need for cholecystectomy after obesity surgery. Br J Surg. 2012; 99:864–869.

32. Papasavas PK, Gagné DJ, Ceppa FA, Caushaj PF. Routine gallbladder screening not necessary in patients undergoing laparoscopic Roux-en-Y gastric bypass. Surg Obes Relat Dis. 2006; 2:41–46. discussion 46–47.

33. Ellner SJ, Myers TT, Piorkowski JR, Mavanur AA, Barba CA. Routine cholecystectomy is not mandatory during morbid obesity surgery. Surg Obes Relat Dis. 2007; 3:456–460.

34. Patel JA, Patel NA, Piper GL, Smith DE 3rd, Malhotra G, Colella JJ. Perioperative management of cholelithiasis in patients presenting for laparoscopic Roux-en-Y gastric bypass: have we reached a consensus? Am Surg. 2009; 75:470–476. discussion 476.

35. Tarantino I, Warschkow R, Steffen T, Bisang P, Schultes B, Thurnheer M. Is routine cholecystectomy justified in severely obese patients undergoing a laparoscopic Roux-en-Y gastric bypass procedure? A comparative cohort study. Obes Surg. 2011; 21:1870–1878.

36. Keus F, de Jong JA, Gooszen HG, van Laarhoven CJ. Laparoscopic versus small-incision cholecystectomy for patients with symptomatic cholecystolithiasis. Cochrane Database Syst Rev. 2006; (4):CD006229.

37. Keus F, de Jong JA, Gooszen HG, van Laarhoven CJ. Laparoscopic versus open cholecystectomy for patients with symptomatic cholecystolithiasis. Cochrane Database Syst Rev. 2006; (4):CD006231.

38. Keus F, de Jong JA, Gooszen HG, van Laarhoven CJ. Small-incision versus open cholecystectomy for patients with symptomatic cholecystolithiasis. Cochrane Database Syst Rev. 2006; (4):CD004788.

39. Lammert F, Neubrand MW, Bittner R, et al. S3-guidelines for diagnosis and treatment of gallstones. German society for digestive and metabolic diseases and german society for surgery of the alimentary tract. Z Gastroenterol. 2007; 45:971–1001.

40. Giger UF, Michel JM, Opitz I, et al. Risk factors for perioperative complications in patients undergoing laparoscopic cholecystectomy: analysis of 22,953 consecutive cases from the Swiss Association of Laparoscopic and Thoracoscopic Surgery database. J Am Coll Surg. 2006; 203:723–728.

41. Tuveri M, Tuveri A. Laparoscopic cholecystectomy: complications and conversions with the 3-trocar technique: a 10-year review. Surg Laparosc Endosc Percutan Tech. 2007; 17:380–384.

42. Duca S, Bãlã O, Al-Hajjar N, et al. Laparoscopic cholecystectomy: incidents and complications. A retrospective analysis of 9542 consecutive laparoscopic operations. HPB (Oxford). 2003; 5:152–158.

43. Huntington CR, Cox TC, Blair LJ, et al. Nationwide variation in outcomes and cost of laparoscopic procedures. Surg Endosc. 2016; 30:934–946.

44. Scott TR, Zucker KA, Bailey RW. Laparoscopic cholecystectomy: a review of 12,397 patients. Surg Laparosc Endosc. 1992; 2:191–198.

45. Danzinger RG, Hofmann AF, Schoenfield LJ, Thistle JL. Dissolution of cholesterol gallstones by chenodeoxycholic acid. N Engl J Med. 1972; 286:1–8.

46. Makino I, Shinozaki K, Yoshino K, Nakagawa S. Dissolution of cholesterol gallstones by long-term administration of ursodeoxycholic acid. Nihon Shokakibyo Gakkai Zasshi. 1975; 72:690–702.

47. Kim TN. Nonsurgical treatment of the gallstone diseases. Chung JB, editor. Diseases of the gallbladder and bile ducts. 1st ed.Seoul: Koonja Publishing;2008. p. 211–218.

48. Podda M, Zuin M, Battezzati PM, Ghezzi C, de Fazio C, Dioguardi ML. Efficacy and safety of a combination of chenodeoxycholic acid and ursodeoxycholic acid for gallstone dissolution: a comparison with ursodeoxycholic acid alone. Gastroenterology. 1989; 96:222–229.

49. Roma MG, Toledo FD, Boaglio AC, Basiglio CL, Crocenzi FA, Sánchez Pozzi EJ. Ursodeoxycholic acid in cholestasis: linking action mechanisms to therapeutic applications. Clin Sci (Lond). 2011; 121:523–544.

50. Bachrach WH, Hofmann AF. Ursodeoxycholic acid in the treatment of cholesterol cholelithiasis. part I. Dig Dis Sci. 1982; 27:737–761.

51. Caroli A, Del Favero G, Di Mario F, et al. Computed tomography in predicting gall stone solubility: a prospective trial. Gut. 1992; 33:698–700.

52. Pereira SP, Veysey MJ, Kennedy C, Hussaini SH, Murphy GM, Dowling RH. Gallstone dissolution with oral bile acid therapy. Importance of pretreatment CT scanning and reasons for nonresponse. Dig Dis Sci. 1997; 42:1775–1782.

53. Petroni ML, Jazrawi RP, Grundy A, et al. Prospective, multicenter study on value of computerized tomography (CT) in gallstone disease in predicting response to bile acid therapy. Dig Dis Sci. 1995; 40:1956–1962.

54. May GR, Sutherland LR, Shaffer EA. Efficacy of bile acid therapy for gallstone dissolution: a metaanalysis of randomized trials. Aliment Pharmacol Ther. 1993; 7:139–148.

55. Grundy SM, Lan SP, Lachin J. The effects of chenodiol on biliary lipids and their association with gallstone dissolution in the National Cooperative Gallstone Study (NCGS). J Clin Invest. 1984; 73:1156–1166.

56. Fromm H, Roat JW, Gonzalez V, Sarva RP, Farivar S. Comparative efficacy and side effects of ursodeoxycholic and chenodeoxycholic acids in dissolving gallstones. A double-blind controlled study. Gastroenterology. 1983; 85:1257–1264.

57. Erlinger S, Le Go A, Husson JM, Fevery J. Franco-Belgian cooperative study of ursodeoxycholic acid in the medical dissolution of gallstones: a double-blind, randomized, dose-response study, and comparison with chenodeoxycholic acid. Hepatology. 1984; 4:308–314.

58. Lanzini A, Jazrawi RP, Kupfer RM, Maudgal DP, Joseph AE, Northfield TC. Gallstone recurrence after medical dissolution. An overestimated threat? J Hepatol. 1986; 3:241–246.

59. Rabenstein T, Radespiel-Tröger M, Höpfner L, et al. Ten years experience with piezoelectric extracorporeal shockwave lithotripsy of gallbladder stones. Eur J Gastroenterol Hepatol. 2005; 17:629–639.

60. Bateson MC, Bouchier IA, Trash DB, Maudgal DP, Northfield TC. Calcification of radiolucent gall stone during treatment with ursodeoxycholic acid. Br Med J (Clin Res Ed). 1981; 283:645–646.

61. Portincasa P, van Erpecum KJ, van De Meeberg PC, Dallinga-Thie GM, de Bruin TW, van Berge-Henegouwen GP. Apolipoprotein E4 genotype and gallbladder motility influence speed of gallstone clearance and risk of recurrence after extracorporeal shockwave lithotripsy. Hepatology. 1996; 24:580–587.

62. Sackmann M, Ippisch E, Sauerbruch T, Holl J, Brendel W, Paumgartner G. Early gallstone recurrence rate after successful shockwave therapy. Gastroenterology. 1990; 98:392–396.

63. Villanova N, Bazzoli F, Taroni F, et al. Gallstone recurrence after successful oral bile acid treatment. A 12-year follow-up study and evaluation of long-term postdissolution treatment. Gastroenterology. 1989; 97:726–731.

64. Petroni ML, Jazrawi RP, Pazzi P, et al. Risk factors for the development of gallstone recurrence following medical dissolution. The British-Italian Gallstone Study Group. Eur J Gastroenterol Hepatol. 2000; 12:695–700.

65. Lazaridis KN, Gores GJ, Lindor KD. Ursodeoxycholic acid ‘me-chanisms of action and clinical use in hepatobiliary disorders’. J Hepatol. 2001; 35:134–146.

66. Doran J, Keighley MR, Bell GD. Rowachol–a possible treatment for cholesterol gallstones. Gut. 1979; 20:312–317.

67. Ellis WR, Rose DH, Richmond CD, Nehru AY, Middleton A, Bell GD. Radio-opaque gallstones-reduction in size and calcium content on treatment with Rowachol. Gut. 1980; 21:A910.

68. Ellis WR, Somerville KW, Whitten BH, Bell GD. Pilot study of combination treatment for gall stones with medium dose chenodeoxycholic acid and a terpene preparation. Br Med J (Clin Res Ed). 1984; 289:153–156.

69. Handelsman B, Bonorris G, Marks JW, Schoenfield LJ. Rowachol and ursodeoxycholic acid in hamsters with cholesterol gallstones. Am J Med Sci. 1982; 284:16–22.

70. Di Ciaula A, Wang DQ, Wang HH, Bonfrate L, Portincasa P. Targets for current pharmacologic therapy in cholesterol gallstone disease. Gastroenterol Clin North Am. 2010; 39:245–264. viii-ix.